Mystery: why no release of severe data? Regardless
Post# of 148288
(Total Views: 413)
Posted On: 03/06/2021 10:18:00 AM
Mystery: why no release of severe data? Regardless of mystery and/or riddle below, EUA "should be" eminment, per PR "Critical" data and new FDA Chief comments reducing the need for p < 0.05
Remdesivir only shows any efficacy in mild to moderate, no benefit for severe or critical.
(and severe SOC folks are more likely to advance to critical than severe LL folks.)
So LL vs SOC (remdesivir +) in severe, should show reduction in deaths, greater than LL vs SOC (remdesivir +) in critical. (Remdesivir/SOC less benefit)
Thus, LL vs SOC (remdesivir +) in severe should show greater than 24% reduction in deaths, eventhough "absolute" deaths in both Severe groups (SOC & LL) were less than in critical.
To fully grasp the above riddle. Gotta read it 3 times slowly, then spin around twice and do 4 push ups, then read it twice again.
Remdesivir only shows any efficacy in mild to moderate, no benefit for severe or critical.
(and severe SOC folks are more likely to advance to critical than severe LL folks.)
So LL vs SOC (remdesivir +) in severe, should show reduction in deaths, greater than LL vs SOC (remdesivir +) in critical. (Remdesivir/SOC less benefit)
Thus, LL vs SOC (remdesivir +) in severe should show greater than 24% reduction in deaths, eventhough "absolute" deaths in both Severe groups (SOC & LL) were less than in critical.
To fully grasp the above riddle. Gotta read it 3 times slowly, then spin around twice and do 4 push ups, then read it twice again.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼